Cymbalta®
Duloxetine HCl
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$75
With Insurance
$10-30
The Short Version
Evidence summary
Cymbalta (Duloxetine HCl) is a SNRI (Serotonin-Norepinephrine Reuptake Inhibitor) prescribed for Major depressive disorder and Generalized anxiety disorder. FDA-approved in 2004.
Side effects appear within days; therapeutic benefits for depression typically take 2-4 weeks. Pain relief may begin within 1-2 weeks.
The most commonly reported side effects are Nausea (23-25%), Dry mouth (13-15%), Drowsiness / fatigue (10-12%). Most common side effect; usually improves after 1-2 weeks. Take with food.
Most research was funded by the manufacturer — independent replication is limited.
What This Really Costs
Long-term cost projection based on current pricing
Monthly
$35
$20 w/ insurance
without insurance
Annual
$420
$240 w/ insurance
without insurance
10 Years
$4.2K
$2.4K w/ insurance
without insurance
30 Years
$12.6K
$7.2K w/ insurance
without insurance
Lifestyle alternative: $0/month in prescriptions. Exercise (for depression) — Effect size comparable to antidepressants (Cohen's d = 0.
The average American retiree spends $165,000 on healthcare over their lifetime (Fidelity, 2024). Informed choices today compound over decades.
Quick Answers
Now what?
You've read the evidence. Here are your next steps.
FDA Black Box Warning
SUICIDALITY IN CHILDREN AND YOUNG ADULTS
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18-24) in short-term studies. Monitor closely for clinical worsening and suicidal ideation, especially during the first few months and dose changes.
Strict Contraindications
How It Works
Duloxetine inhibits the reuptake of both serotonin and norepinephrine in the brain and spinal cord. In depression, it increases the availability of both neurotransmitters in synaptic gaps. In chronic pain, the norepinephrine component activates descending pain inhibition pathways in the spinal cord — this dual action explains its use for both depression and pain.
Why the side effects happen
Nausea and GI effects come from serotonin receptors in the gut (90% of serotonin is in the GI tract). Blood pressure elevation comes from increased norepinephrine. Sexual dysfunction comes from serotonin's suppression of dopamine in sexual arousal pathways. The severe discontinuation syndrome reflects the brain's adaptation to chronically elevated serotonin and norepinephrine levels.
When Will I Feel It?
Side effects appear within days; therapeutic benefits for depression typically take 2-4 weeks. Pain relief may begin within 1-2 weeks.
Side effects predominate — nausea, dizziness, headache are most intense. Minimal therapeutic benefit yet.
Depression symptoms begin to improve. Pain relief may be noticeable. Side effects usually decreasing.
Full antidepressant effect. This is when response should be assessed and dose adjusted if needed.
Adherence Note
Duloxetine must be taken daily — do not skip doses. Missing even 1-2 doses can trigger discontinuation symptoms (brain zaps, dizziness) due to its relatively short half-life (12 hours).
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Evidence-Based Alternatives for Depression and Chronic Pain
Exercise has strong evidence for both depression and chronic pain — the two primary reasons duloxetine is prescribed. For mild-to-moderate depression, therapy and lifestyle changes show comparable efficacy to medication in many studies.
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Exercise (for depression)
Aerobic exercise 3-5x/week has robust evidence for depression. The SMILE trial found exercise equivalent to sertraline at 16 weeks, with lower relapse rates at 10-month follow-up.
Effect size comparable to antidepressants (Cohen's d = 0.5-0.8) for mild-to-moderate depression
Cognitive Behavioral Therapy (CBT)
CBT is the most studied psychotherapy for depression and chronic pain. For depression, it performs as well as medication in many trials. For chronic pain, CBT improves function even without reducing pain intensity.
NNT ~4 for depression; significant functional improvement in chronic pain
Anti-inflammatory diet
Depression is increasingly linked to systemic inflammation. Diets rich in omega-3s, vegetables, and whole foods and low in ultra-processed food show antidepressant effects.
SMILES trial: Dietary improvement produced remission in 32% vs 8% control
Sleep optimization
Insomnia is both a symptom and a driver of depression. CBT for insomnia (CBT-I) can improve depression even without directly targeting mood.
CBT-I reduces depression severity by 50% in comorbid insomnia-depression
Omega-3 fatty acids (EPA)
EPA-predominant fish oil supplements have modest evidence for depression as adjunctive therapy. The evidence is stronger for EPA than DHA.
Small-to-moderate effect (Cohen's d = 0.2-0.4) as adjunctive treatment
Key Studies
How It Compares
Duloxetine is the most prescribed SNRI and the only one with FDA approval for multiple pain conditions (diabetic neuropathy, fibromyalgia, musculoskeletal pain). Its dual action on mood and pain makes it uniquely versatile — but its discontinuation profile is among the worst of any antidepressant.
Strengths
- Dual action on depression and chronic pain
- 5 FDA-approved indications (most of any SNRI)
- Often effective when SSRIs alone are insufficient
- Less weight gain than many alternatives
Weaknesses
- Extremely difficult discontinuation syndrome
- Capsule formulation makes precise dose reduction challenging
- Nausea rate is high (23-25%)
- Can raise blood pressure
- Hepatotoxicity risk (avoid in heavy drinkers)
Clinically Preferred Alternatives
Global Prescribing & Pricing
Duloxetine is widely prescribed globally for both depression and chronic pain; one of the most multi-indication antidepressants
United States
$40-80/mo
Heavily prescribed for pain + depression overlap; 5 FDA-approved indications
No therapy requirement before prescribing
Usually covered
United Kingdom
~$3-8/mo
NICE recommends for depression, GAD, and diabetic neuropathy
CBT or counseling typically offered alongside
Covered by NHS
France
~$5-12/mo
Used for depression and chronic pain
Psychotherapy reimbursed alongside
Covered by Sécurité Sociale
Germany
~$8-15/mo
Widely prescribed for multimorbid patients
Psychotherapy often preferred as first-line
Covered by GKV
Japan
~$20-40/mo
Increasingly used; approved for depression and pain
Often combined with psychotherapy
Covered by JHIS
Duloxetine is one of the most "multi-purpose" antidepressants — approved for 5 different conditions in the US. This breadth of indications, all established through industry-funded trials, expanded the market enormously. Other countries tend to use it more selectively and pair it with psychotherapy.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
All pivotal trials for duloxetine were funded by Eli Lilly, the manufacturer. Lilly designed, conducted, analyzed, and had editorial control over the key studies leading to FDA approval for depression, GAD, diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain — five separate indications, each expanding the market.
Declared Conflicts of Interest
Eli Lilly funded all major trials. Lead investigators were Lilly employees or received substantial compensation. Lilly was found to have minimized reports of suicidality and hepatotoxicity during the approval process. In 2009, Lilly paid $1.42 billion to settle charges of off-label marketing for multiple drugs including Cymbalta.
Key Efficacy Results
Modest efficacy for depression (NNT ~7); more compelling for chronic pain conditions (NNT ~5 for neuropathy). Discontinuation syndrome is notably severe compared to other antidepressants.
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Duloxetine HCl. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Duloxetine HCl in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| Duloxetine vs Placebo (Depression - Lilly) | PMID:11950987 | |
| Duloxetine for GAD (Lilly) | PMID:15169693 | |
| Duloxetine for Diabetic Neuropathy (Lilly) | PMID:15128046 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Nausea
23-25%Most common side effect; usually improves after 1-2 weeks. Take with food.
Dry mouth
13-15%Sip water frequently; sugar-free gum may help
Drowsiness / fatigue
10-12%May improve over weeks; consider bedtime dosing
Constipation
10-11%Increase fiber and water intake
Decreased appetite
8-10%Monitor weight; some patients lose weight on duloxetine
Dizziness
9-10%Rise slowly; usually improves after first week
Insomnia
10%Take in the morning if sleep is disrupted
Sexual dysfunction
3-10%May affect desire, arousal, or orgasm. Often underreported. Tell your doctor — alternatives exist.
Excessive sweating
6-7%Common with SNRIs; manage with breathable clothing
Increased blood pressure
2-5%SNRIs can raise BP via norepinephrine effect — monitor regularly
Serious Adverse Effects
- • Suicidal ideation (FDA black box — age <25)
- • Serotonin syndrome (with serotonergic drugs)
- • Hepatotoxicity (liver damage — avoid in heavy drinkers)
- • Severe discontinuation syndrome
- • Hyponatremia (low sodium — especially in elderly)
- • Mania activation in bipolar disorder
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Suicidal ideation (FDA black box — age <25)
- Serotonin syndrome (with serotonergic drugs)
- Hepatotoxicity (liver damage — avoid in heavy drinkers)
- Severe discontinuation syndrome
- Brain zaps (electric shock sensations in the head)
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Category C. Third-trimester use associated with neonatal withdrawal syndrome. Weigh risk vs benefit with doctor.
Present in breast milk. Monitor infant for sedation, poor feeding, irritability.
Duloxetine is sometimes prescribed off-label for hot flashes and mood changes during menopause. It is also used for the musculoskeletal pain that can accompany perimenopause. Ask whether your symptoms might have a hormonal component that could be addressed differently.
FDA-approved for GAD in children 7-17. Black box warning for suicidality applies. Not approved for depression in children.
Greater risk of hyponatremia, falls, and bleeding. Start at lower dose.
Not recommended if CrCl <30. Active metabolites accumulate.
Hepatotoxicity risk; duloxetine levels increase significantly with liver impairment.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Duloxetine discontinuation syndrome is among the most severe of any antidepressant. Symptoms include "brain zaps," extreme dizziness, nausea, irritability, insomnia, and electric shock sensations. The capsule formulation makes precise dose reduction difficult because capsules should not be opened or crushed.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Duloxetine has one of the most challenging discontinuation profiles — do NOT stop abruptly
- ·Published tapering approaches describe extremely gradual reductions: 120mg → 90mg → 60mg → 30mg → 20mg, with each step lasting 2-4 weeks minimum
- ·Some clinicians use bead-counting methods (opening capsules and removing beads gradually) — this is off-label but widely practiced when standard dose steps are too large
- ·Cross-tapering to fluoxetine (which has a very long half-life) before discontinuing is another published approach to reduce withdrawal severity
- ·Research shows that the 30mg → 0 step is often the most difficult — consider holding at 20mg for 4+ weeks
Warning Symptoms — Contact Your Doctor If You Experience:
- Brain zaps (electric shock sensations in the head)
- Severe dizziness or vertigo
- Extreme irritability or emotional lability
- Nausea, vomiting, diarrhea
- Insomnia
- Flu-like symptoms (muscle aches, chills, sweating)
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.Would therapy alone be enough for my level of depression?
- 2.What is the plan for eventually coming off this medication?
- 3.How bad is the discontinuation syndrome — and how will we manage it?
- 4.Is my pain better addressed by treating the underlying cause?
- 5.Are there non-SNRI options with fewer withdrawal issues?
Lab Tests to Request
- Blood pressure monitoring (SNRIs can raise BP)
- Liver function tests
- Sodium level (risk of hyponatremia in elderly)
- Mood and suicidality screening (first 3 months)
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Cymbalta®
- What is Cymbalta® used for?
- Cymbalta® (Duloxetine HCl) is a SNRI (Serotonin-Norepinephrine Reuptake Inhibitor) manufactured by Generic (originally Eli Lilly). FDA-approved indications include: Major depressive disorder; Generalized anxiety disorder; Diabetic peripheral neuropathy; Fibromyalgia; Chronic musculoskeletal pain; Stress urinary incontinence (outside US).
- What are the common side effects of Cymbalta®?
- Common side effects of Cymbalta® include: Nausea (23-25%); Dry mouth (13-15%); Drowsiness / fatigue (10-12%); Constipation (10-11%); Decreased appetite (8-10%).
- How much does Cymbalta® cost?
- Cymbalta® list price is approximately $75. With insurance it typically costs $10-30; without insurance approximately $20-50.
- Who funded the clinical trials for Cymbalta®?
- All pivotal trials for duloxetine were funded by Eli Lilly, the manufacturer. Lilly designed, conducted, analyzed, and had editorial control over the key studies leading to FDA approval for depression, GAD, diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain — five separate indications, each expanding the market.
- How strong is the clinical evidence for Cymbalta®?
- Key studies: HMAQa, HMAQb (depression), HMEH (GAD), multiple fibromyalgia/neuropathy trials. Modest efficacy for depression (NNT ~7); more compelling for chronic pain conditions (NNT ~5 for neuropathy). Discontinuation syndrome is notably severe compared to other antidepressants. Potential conflicts of interest: Eli Lilly funded all major trials. Lead investigators were Lilly employees or received substantial compensation. Lilly was found to have minimized reports of suicidality and hepatotoxicity during the .
- Are there non-drug alternatives to Cymbalta®?
- Exercise has strong evidence for both depression and chronic pain — the two primary reasons duloxetine is prescribed. For mild-to-moderate depression, therapy and lifestyle changes show comparable efficacy to medication in many studies. See the Alternatives tab for full details.
Get notified when we update Cymbalta®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.